On 3/11/25, Avalo Therapeutics Inc (NASDAQ: AVTX) stock enjoyed a major increase of 11.1%, closing at $7.99. Moreover, this advance was accompanied by exceptionally high trading volume at 1455% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 19.3% during the last week.
Current PriceTarget Research Rating
Avalo Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing complementary signals. Avalo Therapeutics has a slightly negative Appreciation Score of 31 and a very low Power Rating of 2, and the Lowest Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment